Background. Human immunodeficiency virus type 1 (HIV-1) is divided into subtypes and circulating recombinant forms (CRFs) but the impact of subtype/CRF on disease progression is not fully understood.
(O) group, and the non-M/non-O (N) group. Most HIV-1 isolates cluster in the M group, which includes 9 subtypes (A-D, F-H, J, K), a few sub-subtypes (A1-A3 and F1-F2) and at least 50 circulating recombinant forms (CRFs) [4] . West Africa has a genetically diverse HIV epidemic, with several cocirculating subtypes and CRFs. The dominant subtypes/CRFs in this region are CRF02_AG, which accounts for 50%-70% of the infections, and subtype A, which accounts for 10%-20% of the infections [5] [6] [7] [8] . Detailed phylogenetic analyses have previously demonstrated that most of the subtype A sequences isolated in West Africa belong to sub-subtype A3. The emergence of a new recombinant form of A3 and CRF02_AG has also been reported in West Africa [6, 8] .
The different HIV-1 subtypes/CRFs have been suggested to differ in biological properties, such as cellular tropism, syncytium-inducing capacity, viral fitness, and plasma viral load [9] [10] [11] [12] [13] [14] [15] . However, it remains unclear whether differences in biological properties may influence infectivity, transmissibility, and the rate of disease progression. Most studies investigating variations in disease progression have focused on subtype B, the major subtype in North America and Europe [16, 17] . Studies of non-B subtypes in sub-Saharan Africa have shown inconsistent results [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Most studies compared subtype A to 1 or more subtypes/CRFs and found that individuals infected with non-A subtypes/CRFs, and especially subtype D, tended to display a faster disease progression compared with subtype A [18, [20] [21] [22] [24] [25] [26] [27] [28] [29] . However, many of these studies lacked estimated dates of seroconversion, a common limitation of longitudinal studies of disease progression [18, 19, 21, 23, 25, 29] . In addition, some studies combined several subtypes/CRFs into 1 group and compared that group with the dominating subtype, making the results difficult to interpret [23, 25, 27, 28] . One study on disease progression in a seroincident cohort that included recombinant variants showed that recombinant variants were associated with a faster disease progression compared with subtype A, although the different recombinant variants were not stratified into separate groups [27] .
In this study of a seroincident cohort with long follow-up, we investigate differences in disease progression between individuals infected with the 3 major HIV-1 subtypes/CRFs in Guinea-Bissau: A3, CRF02_AG, and A3/CRF02_AG (a recombinant of A3 and CRF02_AG). We determined the subtype/ CRF based on sequencing of the C2-V3 region of env. Disease progression was measured as the time from estimated seroconversion to AIDS and AIDS-related death and as change in lymphocyte count over time.
METHODS

Study Population
Samples analyzed in this study were obtained from individuals enrolled in a cohort of police officers in Guinea-Bissau formed in 1990, described in detail elsewhere [30, 31] . Blood plasma samples were collected at inclusion and at follow-up visits scheduled with an interval of 12-18 months. Inclusion was temporarily closed from June 1998 until the end of 2002 because of the civil war in 1998-1999. However, annual controls of previously included individuals were resumed in July 2000. Follow-up was continued until the end of February 2011. Antiretroviral therapy was introduced in Guinea-Bissau in 2005 through a national treatment program. The police cohort was included in the program in early 2006. All individuals included in this study were treatment naive, except for 5 individuals who were censored on the date of antiretroviral therapy initiation. Individuals who had not been examined since 31 December 2008 were considered lost to follow-up. HIV testing was performed at the National Public Health Laboratory, Bissau, as previously described [30] . The cohort includes 225 HIV-1 seroincident individuals with estimated dates of seroconversion, defined as the midpoint between the last seronegative and the first seropositive sample. In total, samples were available for 191 individuals.
Amplification and Sequence Analysis
Viral RNA was extracted from blood plasma samples, amplified by reverse-transcription polymerase chain reaction and the C2-V3 region (460 bp) was sequenced (described in detail in the Supplementary Methods). For 46 of the 225 HIV-1 seroincident individuals, the viral sequence has been described and subtyped previously (for accession numbers, see Supplementary Table 1 ) [8] . For consistency, we verified the subtype/CRF of those sequences together with the newly described sequences, as described in the Supplementary Methods.
Subtype Determination and Recombination Analysis
Maximum-likelihood trees were reconstructed to determine the HIV-1 subtype/CRF. Putative recombinant sequences of subsubtype A3 and the CRF02_AG were identified by BootScan analysis, using SimPlot v3.5 [32] . Sequences of A3 and CRF02_AG were used as parental sequences, and sequences of A1 were used as out-group sequences (the expanded reference dataset is described in detail in the Supplementary Methods). The break-points of the recombinant sequences, estimated by the BootScan analysis, were all located near the center of the C2-V3 sequences. The sequences were therefore split at the midpoint into 2 fragments of 230-bp, and maximum-likelihood phylogenetic trees were reconstructed for each fragment, as described in the Supplementary Methods. Sequences for which 1 fragment clustered within the A3 cluster and the other within the CRF02_AG cluster were considered to be C2-V3-based A3/ CRF02_AG recombinants, hereafter referred to as A3/02 recombinants.
Epidemiological and Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics 20 [33] . Progression times to AIDS and AIDS-related death were analyzed by Kaplan-Meier survival analysis (log-rank test), and hazard ratios of AIDS or AIDS-related death were analyzed by the Cox proportional hazard analysis (Wald test). AIDS was defined as clinical stages World Health Organization 4 and US Centers for Disease Control and Prevention C, CD4 + T-cell counts <200 cells/µL, CD4 percentage counts <14% or reported AIDS-associated death. Changes in absolute and percentage lymphocyte counts over time were analyzed for individuals with >2 CD4 + or CD8 + T-cell determinations using a linear mixed model with time from estimated date of seroconversion as covariable. Categorical variables were compared using 2-tailed Fisher's exact test, whereas continuous variables were compared using the Mann-Whitney 2-tailed U test.
Ethics
The study was approved by the Research Ethics Committee at the Karolinska Institute, Stockholm, and the Ministry of Health in Guinea-Bissau. Study participants were counseled and provided informed oral consent.
Nucleotide Sequence Accession Numbers
The sequences reported here have been deposited into the GenBank database under accession numbers KF241172-KF241277.
RESULTS
Study Population Characteristics
Among 191 available samples from HIV-1 seroincident individuals residing in Guinea-Bissau, RNA amplification and sequencing of the C2-V3 region was successful for 152 individuals. Five sequences could not be assigned a subtype/CRF and were excluded from further analyses. For the remaining 147 individuals, subtype/CRF distribution was similar to previous estimates from Guinea-Bissau [8] , with the dominating viral variant being CRF02_AG (53%, n = 78) followed by sub-subtype A3 (29%, n = 42). Twenty-two individuals (15%) were infected with a recombinant virus of sub-subtype A3 and CRF02_AG. The majority of the recombinant viruses (n = 19) were A3/CRF02_AG recombinants (A3/02, the first part of the C2-V3 fragment was of sub-subtype A3, the second part was of CRF02_AG). The 3 individuals infected with CRF02_AG/A3 recombinant viruses (the first part of the C2-V3 fragment was of CRF02_AG, the second part was of sub-subtype A3) were excluded from further analyses along with 5 individuals infected with subtype C (n = 2), CRF06_cpx (n = 2), and subtype B (n = 1). The median time from enrollment until endpoint was 10.7 years (interquartile range [IQR], 5.8-14.6 years), and the median observation time from estimated date of seroconversion until endpoint was 5.6 years (IQR, 3.5-8.2 years) for the 139 individuals infected with A3, CRF02_AG, or A3/02 included in the final analysis. Among these individuals, 81% were men. There were no significant differences in sex, age at seroconversion, time from last HIV-1 negative to first HIV-1 positive sample, or loss to follow-up between the different subtype/CRF groups ( Table 1 ). The median estimated date of seroconversion was more recent for sub-subtype A3 (28 January 2005) compared with CRF02_AG (4 January 2000; P < .001) and A3/02 (31 January 2000; P = .02). The median observation time from seroconversion to endpoint was shorter for A3 (4.1 years; IQR, 2.2-8.4) compared with CRF02_AG (6.2 years; IQR, 4.0-8.3; P = .04). A lower percentage of individuals progressed to AIDS and AIDS-related death in the A3 group (40% and 21%, respectively) compared with the CRF02_AG (58%, P = .09; and 40%, P = .05, respectively) and A3/02 (74%, P = .02; and 47%, P = .07, respectively) groups.
Epidemiological Analysis
Kaplan-Meier analyses were performed to investigate differences in time to AIDS and AIDS-related death between the different C2-V3-based subtype/CRF groups ( Figure 1 ). The estimated median time from seroconversion to AIDS was longer for individuals infected with sub-subtype A3 (7.2 years; IQR, 5.6-8.8 years) compared with A3/02 (5.0 years; IQR, 3.1-6.8 years), although the difference was not significant (P = .05). For individuals infected with CRF02_AG, the estimated median time was intermediate (6.2 years; IQR, 4.8-7.6 years) and not significantly different from either A3 (P = .50) or A3/ 02 (P = .13). We obtained similar results using Cox proportional hazard models, both in the unadjusted and adjusted model (adjusted for sex and age at seroconversion) ( Table 2 ). The adjusted hazard ratio for progression to AIDS was 2.6 (P = .01) comparing individuals infected with A3/02 to sub-subtype A3. Analyses of time to AIDS-related death showed similar differences between the subtype/CRF groups. The estimated median time from seroconversion to AIDS-related death was longer for individuals infected with sub-subtype A3 (11.3 years; IQR, 8.2-14.4 years), intermediate for CRF02_AG (9.0 years; IQR, 7.9-10.1 years; P = .06), and shorter for the A3/02 group (8.0 years; IQR, 7.6-8.4 years; P = .22). The adjusted hazard ratios for AIDS-related death were 2.2 comparing CRF02_AG to subsubtype A3 (P = .05) and 2.9 comparing A3/02 to A3 (P = .03). We also performed analysis stratified on sex. The analyses of men only showed nearly identical time estimates from seroconversion to AIDS and AIDS-related death (Table 1) , and similar adjusted HRs (Table 2) . A stratified analysis for women only was not performed because of the small sample size.
CD4
+ and CD8 + T cells
To study the differences in lymphocyte counts over time (CD4 + T-cell count, CD4 + T-cell percentage, CD8 + T-cell count, CD8 + T-cell percentage), we performed a full-factorial linear mixed model with time from estimated date of seroconversion as the covariable. We were thereby able to compare the extrapolated levels at seroconversion and the rates of decline/increase in Tcell absolute counts and percentages (Table 3) . Only individuals with >2 CD4 + T-cell measurements were included in the analysis, representing 46% of the study population. We did not find significant differences between the subtype/CRF groups at the extrapolated level at seroconversion or the rate of CD4 + Tcell absolute count and percentage decline. CD8 + T-cell changes over time could not be analyzed in a mixed model because of an insufficient number of data points. sub-subtype A3 and the recombinant forms CRF02_AG and A3/02, which have previously been reported in other West African countries [5] [6] [7] . We found that individuals infected [20, 22, 24, [26] [27] [28] . One study reported that subtype D, multiple subtype infections within the same individual, and recombinant viruses were all associated with a faster progression to AIDS compared with subtype A [27] . Two studies have failed to show significant differences in disease progression comparing CRF02_AG with Cox proportional hazard model was used to estimate unadjusted and adjusted hazard ratios by human immunodeficiency virus type 1 subtype/circulating recombinant form.
Abbreviations: CI, confidence interval; CRF, circulating recombinant form; HR, hazard ratio. a Adjusted for sex and age at estimated date of seroconversion for all cases and b Adjusted for age at estimated date of seroconversion for only men.
c Hazard ratios were estimated using A3 as reference group. , but these studies were performed on individuals lacking estimated dates of seroconversion [23, 29] . To our knowledge, this is the first study reporting estimates for the time from seroconversion to AIDS-related death for Alike subtypes/CRFs (A3, CRF02_AG, and A3/02), reflecting the long follow-up time of the participants in this study. Most studies have not allowed estimates of time to AIDS or AIDSrelated death because of limited follow-up times. In this study, the survival time from AIDS to death is longer than reported by others. Survival times after AIDS onset have previously been reported to approximately 10 months [34] [35] [36] [37] . However, these estimates represent the time from clinical AIDS to death. In contrast, the vast majority of the individuals in our cohort were diagnosed with AIDS based on CD4 + T-cell counts rather than clinical symptoms. Our estimates from AIDS to death (ranging 32.4-46.8 months, based on CD4 + T-cell counts) is in agreement with what others have reported (ranging 28.4-40.1 months) [38] . Compared with other subtypes/CRFs, A3/02 is associated with the shortest estimated time to AIDS reported to date, except for 1 study on subtype C, which reported an estimated time to AIDS of 4.3 years [20] . However, another study on subtype C reported that 70% of the individuals remained AIDS-free after 6.3 years of infection [24] . Studies of other recombinant forms and superinfection with multiple subtypes/ CRFs have estimated times from seroconversion to AIDS similar to what we report here for A3/02 and CRF02_AG. Our estimate for sub-subtype A3 is also similar to that shown for subtype A. We report estimated times from seroconversion to AIDS-related death for A3/02 and CRF02_AG that are in the range of what others have shown for non-A subtypes (6.9-7.7 years for subtypes C and D) [22, 24, 26, 39] , which is considerably faster than what we report for sub-subtype A3 (11.3 years).
We have previously shown that A3 and CRF02_AG were introduced into Guinea-Bissau at a similar time, followed by similar demographic growth [8] . Consistent with this, the first seroconversion event for each subtype/CRF in this study was estimated to similar dates. However, the median date of seroconversion was more recent in time for sub-subtype A3 compared with CRF02_AG and A3/02, suggesting a slower rate of spread for A3 compared with the recombinant forms. The differences in median date of seroconversion likely also explain the differences we found in incidence of AIDS and AIDS-related death. A higher percentage of individuals progressed to AIDS and death in the recombinant groups (CRF02_AG and A3/02) compared with sub-subtype A3. However, these differences are most likely only attributes of differences in observation time and do not influence our analysis because observation time is taken into consideration in the survival analysis models.
The course of an HIV infection is characterized by a progressive decline in CD4 + T cells, correlated to disease progression.
No significant differences were found between the subtypes/ CRFs in CD4 + T-cell counts or percentages, neither at intercept nor in rate of decline. However, although not statistically significant, the individuals infected with A3/02 had a higher mean rate of decline in CD4 + T-cell counts and percentages compared with those infected with sub-subtype A3. Further studies on larger patient cohorts are needed to elucidate the correlation between disease progression and CD4 + T-cell decline in different subtype/CRF groups. Based on our findings that the C2-V3-based A3/02 recombinant is associated with a faster progression to AIDS and AIDSrelated death, it is tempting to speculate that recombinant HIV-1 forms are more pathogenic than the parental forms. In vitro studies comparing replicative capacity of CRF02_AG with the parental strains A and G suggested that CRF02_AG was associated with a higher replicative capacity compared with both parental strains [40, 41] . HIV-1 subtypes have also been suggested Number of individuals from each study group that had >2 CD4 + T-cell measurements and that were included in the analysis. Data points are the total number of CD4 + T-cell percentage or count measurements included in the analysis.
to differ in biological properties such as coreceptor use. The switch from CCR5 to CXCR4 is associated with faster disease progression [9] , and, in a previous study, we observed a higher frequency of CXCR4-using viruses in late-stage disease among CRF02_AG compared with A3 [12] . It is possible that differences in disease progression are related to differences in coreceptor tropism and/or replicative capacity. It would be interesting to investigate if disease progression rate is correlated to viral load, providing knowledge on how replicative capacity influences disease progression. Because viral load measurements were not included as a standard procedure in GuineaBissau during the sampling period, we were not able to include this parameter. Further studies on the relationship between subtypes, disease progression, viral load and biological properties are needed to better understand the impact of HIV-1 subtype/CRF on disease progression. It should be noted that sequence subtype in this study was assigned based on a relatively short fragment of the C2-V3 region of env (460 bp). The whole genome structure of these sequences may be more complex and possibly include additional break-points. We decided to not combine the 2 identified recombinant forms (A3/02 and 02/A3) into 1 group because they do not represent the same recombinant form and may therefore differ in disease progression.
In conclusion, we show that A3/02 is associated with a faster progression to AIDS and AIDS-related death compared with sub-subtype A3. Furthermore, individuals infected with A3/02 have, compared with other subtypes/CRFs, the fastest progression to AIDS reported to date. To our knowledge, time to AIDS-related death for non-B subtypes has previously only been reported for subtype C, subtype D, and a group of different recombinant forms. We report here, estimates of time from seroconversion to AIDS-related death for the C2-V3-based recombinant forms CRF02_AG and A3/02 and the nonrecombinant form A3. Further studies are warranted to ascertain whether particular subtypes are associated with faster disease progressions than others. Knowledge on the HIV-1 subtype/ CRF of infected individuals could be of importance in the management of HIV-1 infections.
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